An interventional study of OCEAN in Rhinosinusitis Chronic, Wound Healing and Sinus Surgery, sponsored by Polyganics BV. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Polyganics BV · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Rhinosinusitis with a site in United States — 11 open to participants now, 18 under way, 7 of them phase 3. Rhinosinusitis · United States.
Among the 71 studies in Rhinosinusitis with a site in United States, this one is the 49th largest by enrollment of the 55 interventional ones that give a count, is one of 7 that started in 2025, is one of 17 with no phase, and was the 58th registered.
252 studies on the registry are indexed under Rhinosinusitis; 70 are open to participants now.
Browse Rhinosinusitis studies →11 of the 71 studies in Rhinosinusitis with a site in United States are open now. Recruiting first, the newest first:
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Airiver Medical, Inc. · Sites in United States
Ages 18+
Optinose US Inc. · Sites in United States
Ages 12–17
Cedars-Sinai Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
The European Forum for Research and Education in Allergy and Airway Diseases · Sites in United States, Belgium, Canada and 8 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Rhinosinusitis studies recruiting now, 15 (44%) set no upper age limit and 13 (38%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 15 · Phase 4 12
First in 2003; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 74 across 177 interventional studies indexed under Rhinosinusitis.
Median enrollment 59 across the 55 interventional studies, 70 across the 16 observational. Of the 46 that completed or were terminated, 24 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 71 have an industry lead sponsor. The 10 most frequent:
Polyganics BV is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Polyganics BV has 2 studies filed under Rhinosinusitis — fewer than ten, so there is no comparison to draw.
10 of the studies in Rhinosinusitis with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06706817Phase 3AstraZenecaA Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab | 2027-01-13 |
| NCT07424144Phase 3SanofiAn Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps | 2027-02-17 |
| NCT06338995Phase 3Eli Lilly and CompanyA Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) | 2027-05 |
| NCT06567821Phase 3Cedars-Sinai Medical CenterUsing Navigation to Improve Accuracy of Maxillary Balloon Sinusotomy | 2027-10-01 |
| NCT02038166University of Alabama at BirminghamNasal Potential Difference (NPD) Protocol in Chronic Rhinosinusitis | 2026-12 |
Add all 10 to your calendar (.ics) → With an account.
Among the 71 studies in Rhinosinusitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to investigate the safety and performance of OCEAN® as an adjunct in wound healing after nasal/sinus surgery by using OCEAN® in patients undergoing nasal/sinus surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Application of OCEAN after nasal/sinus surgery
Device: OCEAN
Biodegradable nasal dressing
Rate of Serious Adverse Events
Rate of serious adverse events related to the use of the OCEAN bioresorbable nasal dressing post nasal surgery
Time frame: Up to 25 days after surgery
Performance
Endoscopic evaluation of aspects of wound healing as assessed using the Lund-Kennedy Endoscopic Score System (LKS). The LKS assesses various factors like edema, crusting, discharge, polyps, and mucosal inflammation. Each parameter is scored from 0 to 2, with 0 being normal and 2 representing severe findings. Higher scores on the Lund-Kennedy Scale indicate a worse outcome, reflecting more severe disease or poor wound healing. Minimum Value: 0 (This represents no signs of inflammation or disease); Maximum Value: 20 (This indicates the most severe signs of disease or inflammation)
Time frame: Up to 25 days after surgery
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2025 to primary completion in Jun 2025, 4 months.
Of 33 interventional studies with no phase under Rhinosinusitis, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 36. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Polyganics BV